-
MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma
30 Jan 2025 19:32 GMT
… MB-105 has received orphan drug designation from the … regulatory milestone, securing orphan drug designation for MB-105 …
March Biosciences receives FDA orphan drug designation for MB-105 … March-Biosciences-Receives-FDA-Orphan-Drug-Designation-for-MB-105 …
-
March Biosciences receives US FDA orphan drug designation for MB─105 to treat relapsed/refractory CD5─positive T─cell lymphoma
30 Jan 2025 12:15 GMT
… and Drug Administration (FDA) granted orphan drug designation to MB-105, the … an important regulatory milestone, securing orphan drug designation for MB-105 from … people in the United States. Orphan Drug designation provides various development incentives …
-
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
29 Jan 2025 21:44 GMT
… granted MB-105 orphan drug designation for the treatment …
The FDA has granted orphan drug designation to MB-105 … important regulatory milestone, securing orphan drug designation for MB-105 …
March Biosciences receives FDA orphan drug designation for MB-105, …
-
CD5 CAR-T Cell Therapy Receives FDA Orphan Drug Designation for T-Cell Lymphoma
29 Jan 2025 20:56 GMT
… FDA has granted orphan drug designation to MB- … important regulatory milestone, securing orphan drug designation for MB-105 … March Biosciences Receives FDA Orphan Drug Designation for MB-105, … March-Biosciences-Receives-FDA-Orphan-Drug-Designation-for-MB-105- …
-
FDA Grants Orphan Drug Designation to ZL-1310 for Treatment of Small Cell Lung Cancer
29 Jan 2025 16:43 GMT
The FDA granted orphan drug designation (ODD) to Zai Lab … Lab Limited. Zai Lab receives orphan drug designation from the U.S … ;en/Zai-Lab-Receives-Orphan-Drug-Designation-from-the-U.S …
-
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
03 Feb 2025 22:00 GMT
… , such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy …
-
UniQure Completes Enrollment In The First Cohort Of Phase I/IIa Trial Of AMT-191 In Fabry Disease
03 Feb 2025 22:35 GMT
… -162 has been granted both Orphan Drug status and Fast Track designation …
-
FDA receives biologics license application for apitegromab in spinal muscular atrophy
03 Feb 2025 18:54 GMT
… previously been granted fast-track, orphan drug and rare pediatric disease designations …
-
2021 was the leading year in rare disease trials
03 Feb 2025 16:42 GMT
… European Medicines Agency such as orphan drug designations and PRIME designations have …
-
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
03 Feb 2025 16:18 GMT
… prescription drug, has been granted Orphan Drug Designation by the FDA and … region.
Crofelemer has been granted Orphan Drug Designation by the U.S …